Clinical Research Directory

Key Inclusion Criteria: * The participant has been treated with asedebart in a clinical trial. * The participant had an acceptable benefit-risk assessment in the prior trial and would benefit from continued treatment with asedebart in the opinion of the investigator. * For participants with \> 12 weeks since their last dose of asedebart: The participant has been on a stable daily dose of GC replacement therapy of ≥ 8 milligram per square meter (mg/m\^2) (adjusted for body surface area in hydrocortisone equivalent dosage \[HCe\]) for \>= 1 month prior to the Screening Visit. * For participants with \> 12 weeks since their last dose of asedebart: The participant is not adequately controlled on their current treatment and, at the Screening/Baseline Visit, has either: * elevated androgen blood concentrations (A4 \> upper limit of normal (ULN) for age and sex) in morning measurements (pre-GC replacement dose) OR * androgen blood concentrations within the reference range (A4 \<= ULN for age and sex) and is being treated with supraphysiological GC (GC daily dose \> 13 mg/m\^2 adjusted for body surface area in HCe) Key Exclusion Criteria: * The participant has known hypersensitivity or intolerance to asedebart or its excipients. * The participant has taken any investigational medicinal product (IMP) other than asedebart \< 3 months or \< 5 half-lives, whichever is longer, prior to the first dose of asedebart in this trial. * The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods. * The participant has an increased risk of adrenal crisis in the opinion of the investigator (for example history of repeated adrenal crisis in recent years, history of adrenal crisis caused by reduction of GC dose). Other protocol-defined criteria apply.